Review
Version 3
This version is not peer-reviewed
Potential Biomarkers for Cervical Cancer Screening and Treatment
Version 1
: Received: 11 October 2020 / Approved: 12 October 2020 / Online: 12 October 2020 (10:14:44 CEST)
Version 2 : Received: 1 December 2020 / Approved: 1 December 2020 / Online: 1 December 2020 (15:09:12 CET)
Version 3 : Received: 30 March 2021 / Approved: 30 March 2021 / Online: 30 March 2021 (09:32:47 CEST)
Version 2 : Received: 1 December 2020 / Approved: 1 December 2020 / Online: 1 December 2020 (15:09:12 CET)
Version 3 : Received: 30 March 2021 / Approved: 30 March 2021 / Online: 30 March 2021 (09:32:47 CEST)
How to cite: Uyeda, M. Potential Biomarkers for Cervical Cancer Screening and Treatment. Preprints 2020, 2020100220 Uyeda, M. Potential Biomarkers for Cervical Cancer Screening and Treatment. Preprints 2020, 2020100220
Abstract
Cervical cancer (CC) is the most common cancer in women worldwide and is almost always associated with repeated infections by human papillomavirus (HPV). Screening by traditional tests combined with biomarker identification techniques for low- or high-grade injuries, are becoming increasingly important in diagnosis and prognosis, avoiding countless deaths. This article explores existing literature on the main serum biomarkers and the identification of biomarkers associated with the oncogenesis of HPV expression in the identification of pre-cancerous lesions and of CC for an effective treatment, with reduction of recurrence, as well as we explain strategies for the development of biomarkers based on DNA, proteins and other markers. We also describe how markers of chromosomal instability host DNA, promoting hypo- or hypermethylation of DNA, as well as polymorphisms and epigenetic events in the p53 gene. Finally, we discuss changes in gene expression using cDNA microarray techniques and changes in the expression of proteins and markers identified through mass spectrometry.
Keywords
Cervical cancer; Biomarkers; Human papillomavirus; Pap smear; cervical intraepithelial neoplasia
Subject
Medicine and Pharmacology, Immunology and Allergy
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (1)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)
* All users must log in before leaving a comment
Commenter: Mahendran Subramanian
Commenter's Conflict of Interests: Author